drugset
drugset / Trial / NCT06753071

The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder.

NCT06753071 ↗

Phase 4 Completed 66 enrolled Menoufia University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The efficacy of pyridostigmine therapy after transurethral resection of prostate in cases with underactive urinary bladder

Timeline

Start
2024-04-01
Primary completion
2024-07-01
Completion
2025-01-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pyridostigmine Small molecule 60 mg Oral

Indications

benign prostatic hyperplasia urinary bladder disorder